A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics and clinical response of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes

Trial Profile

A randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics and clinical response of repeated subcutaneous doses of E1 in combination with G1 in patients with type 2 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2007

At a glance

  • Drugs Epidermal growth factor (Primary) ; TT 223 (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Transition Therapeutics
  • Most Recent Events

    • 05 Mar 2007 Interim results have been presented (at 3-months post-treatment)
    • 27 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top